Zhaoke Ophthalmology (HKG:6622) entered into an agreement under which it is entitled to grant AFT Pharmaceuticals the exclusive rights to distribute BRIMOCHOLTM PF in Australia and New Zealand, a Monday bourse filing said.
AFT Pharmaceuticals, a manufacturer and distributor of healthcare products based in New Zealand, will obtain the relevant local drug registrations on behalf of the company to import, distribute, promote, market, and sell the drug in the region.
The ophthalmic pharmaceutical company will receive an upfront payment, as well as additional milestone payments under the contract.
BRIMOCHOLTM PF is being developed by Zhaoke Ophthalmology's in partnership with Tenpoint Therapeutics as a potential treatment for the correction of the loss of near vision associated with presbyopia.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。